Ginkgo Bioworks Holdings, Inc.
DNA
$7.54
-$0.27-3.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.85M | 89.05M | 56.21M | 37.94M | 34.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.85M | 89.05M | 56.21M | 37.94M | 34.76M |
| Cost of Revenue | 9.62M | 12.00M | 13.72M | 9.20M | 6.61M |
| Gross Profit | 34.23M | 77.04M | 42.49M | 28.74M | 28.14M |
| SG&A Expenses | 51.99M | 52.29M | 61.77M | 70.29M | 65.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 766.00K | -- | -- |
| Total Operating Expenses | 137.98M | 141.30M | 210.48M | 215.95M | 188.73M |
| Operating Income | -94.14M | -52.26M | -154.28M | -178.00M | -153.97M |
| Income Before Tax | -107.86M | -56.78M | -216.99M | -165.88M | -211.89M |
| Income Tax Expenses | -325.00K | -375.00K | 190.00K | 31.00K | -198.00K |
| Earnings from Continuing Operations | -107.53M | -56.40M | -217.18M | -165.91M | -211.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.53M | -56.40M | -217.18M | -165.91M | -211.69M |
| EBIT | -94.14M | -52.26M | -154.28M | -178.00M | -153.97M |
| EBITDA | -78.49M | -35.09M | -136.95M | -165.13M | -141.14M |
| EPS Basic | -2.00 | -1.08 | -4.23 | -3.31 | -4.28 |
| Normalized Basic EPS | -1.00 | -0.48 | -1.71 | -2.04 | -1.71 |
| EPS Diluted | -2.00 | -1.08 | -4.23 | -3.32 | -4.29 |
| Normalized Diluted EPS | -1.00 | -0.48 | -1.71 | -2.04 | -1.71 |
| Average Basic Shares Outstanding | 53.81M | 52.24M | 51.37M | 50.11M | 49.44M |
| Average Diluted Shares Outstanding | 53.81M | 52.25M | 51.38M | 50.13M | 49.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
